Fundz

Strongbridge Biopharma Plc reported raising $126 Million in an initial SEC Form D filing, from an offering of $126 Million

PRIVATESep 14, 2015

Amount Raised

$126 Million

$126 Million sold, per SEC Form D (first sale Sep 14, 2015)

Round Type

Venture

TrevoseBiotechnologyHealthcareHealth CareScience And Engineering

Quick answer

Strongbridge Biopharma plc raised $126 Million in a funding round, dated September 14, 2015. Strongbridge Biopharma plc is based in Trevose, Pennsylvania, United States.

How much did Strongbridge Biopharma plc raise?
Strongbridge Biopharma plc raised $126 Million in a funding round on September 14, 2015.
What does Strongbridge Biopharma plc do?
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs.
Where is Strongbridge Biopharma plc based and how big is it?
Strongbridge Biopharma plc is based in Trevose, Pennsylvania, United States.

Source: Fundz verified event record.

Who else raised in Healthcare and Science And Engineering around the same time

Companies in the same sectors as Strongbridge Biopharma plc that raised within 45 days of this round, from Fundz verified event records.

  • Checkmate Pharmaceuticals, Inc. raised $10M on August 25, 2015.
  • CytoDyn raised $2.7M (Seed) on October 5, 2015.
  • Deciphera Pharmaceuticals raised $22M on September 29, 2015.
  • Corvus Pharmaceuticals, Inc. raised $75M on September 25, 2015.
  • Eximis Surgical raised $270K (Seed) on September 23, 2015.
  • TransMedics Group raised $500K on September 21, 2015.

Who to call at Strongbridge Biopharma plc, and when

A new round usually means Strongbridge Biopharma plc is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Strongbridge Biopharma plc raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Strongbridge Biopharma plc, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Strongbridge Biopharma plc. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Strongbridge Biopharma plc

Location

900 NORTHBROOK DRIVE

Trevose, Pennsylvania, United States

About

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge’s rare endocrine franchise includes RECORLEV® (levoketoconazole), an adrenal steroidogenesis inhibitor with a New Drug Application that is currently under review by the FDA for the treatment of endogenous Cushing’s syndrome, and veldoreotide extended release, a pre-clinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The company’s rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Strongbridge Biopharma plc raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Strongbridge Biopharma plc's next move

See what Strategic adds

Strongbridge Biopharma plc raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.